Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CCR5 | P51681 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3216011 | 0.85 | SLC2A1 (0.33) | MTNR1AMTNR1BSLC2A1HTR2C | |
| SCHEMBL3217443 | 0.85 | SLC2A1 (0.35) | MTNR1AMTNR1BSLC2A1HTR2CCYP2D6 | |
| SCHEMBL3155389 | 0.82 | MTNR1A (0.48) | MTNR1AMTNR1BPRMT5WDR77SLC2A1 | |
| SCHEMBL3154477 | 0.80 | MTNR1A (0.44) | MTNR1AMTNR1BSLC2A1CCR5 | |
| SCHEMBL3551285 | 0.79 | KCNH2 (0.39) | SLC2A1 | |
| SCHEMBL1712390 | 0.73 | MTNR1A (0.46) | MTNR1AMTNR1BHTR2C | |
| SCHEMBL2821724 | 0.71 | KCNH2 (0.43) | SLC2A1 | |
| SCHEMBL2821729 | 0.71 | KCNH2 (0.43) | SLC2A1 | |
| SCHEMBL3144806 | 0.71 | SLC2A1 (0.33) | MTNR1AMTNR1BSLC2A1HTR2CCCR5 | |
| SCHEMBL4428657 | 0.70 | MTNR1A (0.44) | MTNR1AMTNR1BSLC2A1CCR5OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137353-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137353-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | NRDC, NACA, NOP2 | MTNR1A 3390/4885MTNR1B 3097/4885PRMT5 3781/4885 |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | MTNR1A 1695/4885MTNR1B 1409/4885PRMT5 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.